Correlation between Serum Uric Acid and Essential Hypertension by Chandrasekaran, K
1 
 
               CORRELATION BETWEEN 
SERUM URIC ACID AND ESSENTIAL 
HYPERTENSION 
 
 
 
                                       Dissertation Submitted for 
 
                          MD Degree (Branch I) General Medicine 
                                                     March 2010 
 
 
 
 
       The Tamilnadu Dr.M.G.R.Medical University 
                                                  Chennai – 600 032. 
                              Madurai    Medical   College, Madurai  
2 
 
                                        CERTIFICATE 
 
                This is to certify that this dissertation titled “CORRELATION 
BETWEEN SERUM URIC ACID AND ESSENTIAL 
HYPERTENSION” submitted by DR.CHANDRASEKARAN.K to the 
faculty of General Medicine, The Tamil Nadu Dr. M.G.R. Medical 
University, Chennai in partial fulfilment of the requirement for the award of 
MD degree branch I General Medicine, is a bonafide research work carried 
out by him under our direct supervision and guidance. 
 
 
 
 
DR. V.T.PREMKUMAR, M.D.,               DR.A.AYYAPPAN, M.D., 
Professor of Medicine,      Professor and Head 
Chief, VI Medical Unit,              Department of Medicine, 
Department of Medicine,     Madurai Medical College, 
Madurai Medical College,    Madurai 
Madurai                                                    
 
3 
 
DECLARATION 
               I, Dr.CHANDRASEKARAN.K, solemnly declare that the 
dissertation titled “CORRELATION BETWEEN SERUM URIC ACID 
AND ESSENTIAL HYPERTENSION” has been prepared by me. This is 
submitted to The Tamil Nadu Dr. M.G.R. Medical University, Chennai, in 
partial fulfilment of the regulations for the award of MD degree (branch I) 
General Medicine. 
 
 
Place: Madurai 
Date:14/12/2009      DR.CHANDRASEKARAN.K
   
 
 
 
 
 
 
 
 
                                      
4 
 
                                       ACKNOWLEDGEMENT  
At the outset, I thank our Dean Dr. S.M.SIVAKUMAR, M.S., for 
permitting me to use the facilities of Madurai Medical College and 
Government Rajaji Hospital to conduct this study.  
I wish to express my respect and sincere gratitude to my beloved unit 
chief Dr.V.T.PREMKUMAR, M.D., for his valuable guidance and 
encouragement throughout the study and also during my post graduate 
course. I owe my sincere thanks to him.  
I express my special thanks to the department of biochemistry for the 
laboratory support provided.  
I am greatly indebted to my beloved teachers, Dr.A.Ayyapan M.D., 
Dr.MosesK.DanielMD,Dr.S.VadivelMuruganMD,Dr.D.D.Venkatraman,
M.D., Dr. M.Muthiah M.D., Dr.M.Natarajan, M.D. and Dr.J.Sangmani, 
M.D.,  for their valuable advice and guidance throughout my postgraduate 
course. 
 
My sincere thanks to my Assistant Professors Dr.S.Maniappan M.D., 
Dr.D.Ganesapandian M.D., for their constant encouragement, timely help 
5 
 
and critical suggestions throughout the study and also for making my stay in 
the unit both informative and pleasurable. 
I profusely thank the Biochemistry Departments for their cooperation 
and support.  
I extend my thanks to my family and friends have stood by me during 
my times of need. Their help and support have been invaluable to the study. 
Finally, I thank all the patients, who form the most integral part of the 
work, were always kind and cooperative. I pray for their speedy recovery and 
place this study as a tribute to them. 
Above all I thank the Lord Almighty for his kindness and benevolence. 
 
 
 
 
 
 
 
6 
 
                                 CONTENTS 
S.NO.  CONTENTS      PAGE NO. 
1.    INTRODUCTION                                 1                    
2.   REVIEW OF LITERATURE                    4             
3.    AIMS AND OBJECTIVES                      36           
4.   MATERIALS AND METHODS              37        
5.   RESULTS AND ANALYSIS                   43          
6.   DISCUSSION                                         60            
7.    CONCLUSION            67 
       
APPENDIX 
BIBLIOGRAPHY 
PROFORMA 
MASTER CHART 
ETHICAL COMMITTEE APPROVAL FORM 
ABBREVIATIONS 
 
 
7 
 
        INTRODUCTION 
Cardiovascular disease is an epidemic of modern society. 
Hypertension is the most common form of cardiovascular disease 
present in nearly 25% of adults and increases in prevalence with age. 
Cannon et al (1966) reported that hyperuricemia was observed in 25% of 
untreated hypertensive subjects, 50% of those on treatment, and 75% to 
100% of those with malignant hypertension or renal dysfunction. 
Frederick Akbar Mahomed observed that many hypertensive 
subjects came from gouty families, leading him to suggest uric acid as a 
causal factor in the blood pressure response. Haig, who proposed low 
purine diets as a means to prevent hypertension and vascular disease. 
The French academician, Henri Huchard, noted that renal 
arteriolosclerosis (the histological lesion of hypertension) was primarily 
observed in 3 groups: those with gout or lead poisoning or those with a 
diet enriched in fatty meat, all conditions associated with 
hyperuricemias. 
Mazzali et al (2001) has demonstrated that hyperuricemic rats 
develop hypertension which is associated with preglomerular vascular 
disease. Prevention of the renal microvascular lesions during childhood 
might reduce the incidence of hypertension. 
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        Bogalusa Heart Study found that uric acid levels in childhood 
predict the development of diastolic hypertension 10 years later. The 
second study, from the Framingham group, also found uric acid to 
predict the development of hypertension. Not only does uric acid 
predict the development of hypertension, but a recent study suggests 
that elevated uric acid is much more common in the new onset 
hypertensive patient than originally believed. In a study of new onset 
hypertension in adolescents, 89% of children with essential 
hypertension had a uric acid level >5.5 mg/dL versus 30% of secondary 
hypertension and 0% of white-coat hypertensive or control subjects. 
The relationship of uric acid to hypertension was independent of renal 
function or obesity and was strong and linear (r=0.8). Finally, pilot 
studies suggest that lowering uric acid in the new onset hypertensive 
subject can normalize blood pressure, although one must be cautious 
because no placebo group was included.  
           
     The baseline serum uric acid level is a durable marker of risk for the 
development of hypertension. The association is independent of 
elements of the metabolic syndrome, alcohol intake, and renal function. 
(Hypertension. 2006; 48:1031.) 
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       The association of hyperuricemia with hypertension has long been 
recognized. It remains unresolved whether the association of 
hyperuricemia with hypertension is solely because of underlying renal 
and metabolic abnormalities. Decreased renal blood flow and 
decreased tubular secretion of uric acid have been associated with 
hyperuricemia in hypertension. Hyperinsulinemia secondary to insulin 
resistance may also contribute to the association of hyperuricemia with 
hypertension. Recent observations in experimental hyperuricemia 
suggest that uric acid may in fact have a pathogenic role in 
hypertension. Hyperuricemia induces hypertension in experimental 
animals that corrects with hypouricemic therapy. 
       This association was independent of age, body size, central 
adiposity, total cholesterol level, triglyceride level, smoking status and 
alcohol intake, and glucose level. These results demonstrate that the 
SUA level is a durable marker of risk for hypertension.  
        Here an attempt has been made to study the prevalence of 
elevated uric acid levels in essential hypertension and the correlation 
between elevated uric acid levels and hypertensive target organ 
damage.  
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REVIEW OF LITERATURE 
HYPERTENSION 
 Hypertension is the commonest cardiovascular disorder, posing a 
major public health challenge. The individual with of hypertension is 90%.  
The framingham Study have shown that hypertensive patients have a 4 fold 
increase in cerebrovascular accidents, as well as 6 fold increase in 
congestive Heart failure. When compared to Normotensive control subjects. 
It has been estimated that hypertension accounts for 6% of death world 
wide; of all hypertensive patients 90% have essential hypertension.  
 
Definition: 
 Hypertension is defined as elevated arterial pressure that places 
patients at increased risk for target organ damage (TOD). According to 
JNC-VII report Hypertension defined as any one of the following. Systolic 
blood pressure > 140mmHg; Diastolic blood pressure > 90mm Hg and 
those taking anti hypertensive medications.  
                                                                             Stroke volume 
                                           Cardiac output 
                                                                                         Heart rate                 
          Arterial pressure  
                                                                                         Vascular structure 
             Peripheral resistance  
                                                                               Vascular function 
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Classification: 
 JNC – VII included only adults aged 18 yrs and older, Definition 
and classification of hypertension refer to adults not taking anti 
hypertensive drugs and not actually ill, and based on the average of two or 
more reading on two or more occasions after initial screening. 
Table: 1 
Category Systolic B.P. 
(mm Hg) 
 Diastolic B.P. 
(mm Hg) 
Normal  
Pre hypertension 
Hypertension  
Stage I 
Stage II 
     <120 
  120-139 
 
  140-159 
    >160 
   and 
    or 
 
    or 
    or 
     <80 
   80-99 
 
  100-109 
    >110 
 
        Prevalence: 
    In Framingham study, almost one half of the white sub-urban 
population had blood pressure >140/90 mm Hg.  
    In India as per study conducted by Gupta, et al (1977-78) the 
prevalence was 59.9 and 69.9 per 1000 is males and females respectively 
in the urban population and 35.5 and 35.9 per 1000 in males and females 
respectively in the rural population.  
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        Determinants of arterial pressure:  
    Both environments and genetic factors may contribute to regional 
and racial variation of blood pressure and hypertension prevalence.  
 
Diagnosis  Percentage  
Essential Hypertension  >95% 
Renal Hypertension  
                     Parenchymal  2-3% 
 Reno vascular   1-2% 
Endocrine Hypertension   
 Primary aldosteronism  0.3% 
 Cushing’s syndrome  <0.1% 
 Pheochromocytoma  <0.1% 
 OCP Induced   2-3% 
Miscellaneous   
Coarctation of aorta, PAN, 
Neurogenic and Drug Induced  
  1% 
 
¾ No specific cause is known for >95% of hypertension and the 
condition is known as essential hypertension.      
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¾ The onset is usually between ages 25 and 55 years; it is uncommon 
before age 20 years.    
¾ Secondary hypertension constitutes only 2-5% of total hypertensive 
population.  
  
          Mechanism of Essential Hypertension: 
Genetic and Environment Predisposition: 
In studies of twins and family members in which the degree of 
familial aggregation of blood pressure level is compared with closeness 
of genetic sharing, the genetic contributions have been estimated to 
range from 30% - 60%. (Harrap, 1994). Unquestionably environment 
plays some role and Harrap offers as a working model an interaction 
between genes and environment in which the average population 
pressure is determined by environment but the blood pressure rank 
within the distribution is decided by genes. Genetic abnormalities may 
be monogenic as in Liddle syndrome; glucocorticoid remediable 
aldosteronism and apparent mineralocorticoid excess (Luft, 1998) or 
involves polymorphism of genes involving Renin angiotension system 
(Staessen et al, 1999), Aldosterone system or adrenergic receptors. 
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Abnormal cardiovascular or renal development: 
     In normal cardiovascular system elasticity of the great arteries is 
matched to the resistance in the periphery to optimize large vessel 
pressure waves. In this way, myocardial oxygen consumption is 
minimized and coronary flow maximized.1.Elevated blood pressure 
later in life could arise from abnormal development of reduced aortic 
elasticity or reduced development of the microvascular network.2.Low 
birth weight as a consequence of fetal under nutrition is followed by an 
increased incidence of high blood pressure later in life (Law and Shiell, 
1996).3.Brenner and Cherton hypothesized that a decreased number of 
nephrons from the intrauterine growth retardation could very well 
serve as a permanent irreparable defect that eventuates in hypertension 
(Brenner and Cherton, 1996). 
         Renal Retention and Excess of Dietary Sodium: 
A considerable amount of circumstantial evidence supports a 
role for sodium in the genesis of hypertension. To induce hypertension 
some of that excess sodium must be retained by the kidneys. Such 
retention could arise in a number of ways. 
• A decrease in the filtration surface by a congenital or acquired 
deficiency in nephron number or function (Brenner, 1992). 
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• A resetting of pressure - natriuresis relationship (Guyton, 1992). 
• An acquired inhibitor of the sodium pumps (Noolfson et al, 1991). 
• Nephron heterogenecity- presence of a subgroup of nephrons that is 
ischemic either from afferent arteriolar vasoconstriction or from an 
intrinsic narrowing of the lumen (Sealy et al, 1988). 
Vascular Hypertrophy: 
A number of factors increase peripheral resistance by both 
functional contraction and vascular remodeling and hypertrophy. 
Multiple vasoactive substances act as pressure-growth promoters 
resulting in both vascular contraction and hypertrophy, but 
perpetuation of hypertension involves hypertrophy. Lever and Harrap 
postulated (Lever, 1992) that primary hypertension has two 
mechanisms similar to secondary hypertension-(I) a growth promoting 
process in children ,(2) a self - perpetuating mechanism in adults. 
         Neurohumoral Causes of Essential Hypertension: 
A large number of circulatory hormones may be involved in the 
development of hypertension which causes hypertension by vascular 
hypertrophy, capillary rarefaction and impaired micro vascular dilation 
(Pries, 1999). 
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          A) Sympathetic Nervous Hyperactivity: 
This is most apparent in younger persons with hypertension, 
who may exhibit tachycardia and an elevated cardiac output. However, 
correlations between plasma catecholamines and blood pressure are 
poor. Insensitivity of the baroreflexes may play a role in the genesis of 
adrenergic hyperactivity 
          B) Renin–angiotensin system activity: 
Renin is secreted in response to a number of stimuli, including 
reduced renal perfusion pressure, diminished intravascular volume, 
circulating catecholamines, increased sympathetic nervous system 
activity, increased arteriolar stretch, and hypokalemia. Plasma renin 
levels are classified in relation to dietary sodium intake or urinary 
sodium excretion. Renin acts on angiotensinogen to cleave off the ten-
amino-acid peptide angiotensin I. This peptide is then acted upon by 
angiotensin-converting enzyme (ACE) to create the eight-amino-acid 
peptide angiotensin II, a potent vasoconstrictor and a major stimulant 
of aldosterone release from the adrenal glands. The incidence of 
hypertension and its complications may be increased in individuals 
with the DD genotype of the allele coding for ACE. Despite the role of 
this system in the regulation of blood pressure, it probably does not 
play a central role in the pathogenesis of most primary (essential) 
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hypertension; only 10% of patients have high renin activity, whereas 
60% have normal levels, and 30% have low levels. (Brenner, et al, 
1973). 
           C) Hyperinsulinemia / Insulin resistance: 
An association between hypertension and hyper insulinemia has 
been established not only in obese but also non obese hypertension 
(Liese et al, 1998). The Hyperinsulinemia of hypertension arises as a 
consequence of resistance to the effects of insulin on peripheral 
glucose utilization. Insulin has multiple pressor effects (Cardillo, et al, 
1998) including activation of sympathetic activity, trophic action on 
vascular hypertrophy and increased renal sodium absorption. Normally 
The pressor effects are counteracted by insulin mediated increased 
synthesis of nitric oxide. In hypertension there is impairment in the 
insulin mediated increase in nitric oxide leading to rise in blood 
pressure.  
         Endothelial Dysfunction: 
Endothelium is now known to be the source of multiple relaxing 
and contracting substances of which nitric oxide in an important 
vasodilator (Steinberg, et al, 1994). Hypertensive patients have been 
shown to have impaired nitric oxide mediated vasodilatory responses 
(Ruschitzka , et al, 1998). 
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         Other Associated Conditions: 
         Hypertension is associated with other conditions like obesity, 
physical inactivity, sleep apnea, alcohol intake, smoking and 
hyperurcemia.  
Complications of Untreated Hypertension: 
Complications of hypertension are related either to sustained 
elevations of blood pressure, with consequent changes in the 
vasculature and heart, or to atherosclerosis that accompanies and is 
accelerated by long-standing hypertension. Most of the adverse 
outcomes in hypertension are associated with thrombosis rather than 
bleeding, possibly because increased vascular shear stress converts the 
normally anticoagulant endothelium to a prothrombotic state. If 
untreated, 50% of hypertensive patients die of coronary artery disease 
or congestive cardiac failure, about 33% of stroke and 10 - 15% of 
renal failure. The risk approximately doubles for each 6 mm Hg 
increase in diastolic blood pressure. A meta-analysis of nine major 
prospective studies shows a direct continuous and apparently 
independent association of diastolic BP with both coronary artery 
disease and stroke (Mac Mohan, et al 1990). However, target-organ 
damage varies markedly between individuals with similar levels of 
office hypertension; ambulatory pressures are superior to office 
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readings in the prediction of end-organ damage. The various target 
organ damage by hypertension is as follows. 
Table 3Target Organ Damage 
Heart 
• Left ventricular hypertrophy 
• Angina or prior myocardial infarction 
• Prior coronary revascularization 
• Heart failure 
Brain 
• Stroke or transient ischemic attack 
Chronic kidney disease 
Peripheral arterial disease 
Retinopathy 
 
Overall Cardiovascular Risk: 
The degree of risk from hypertension can be categorized with 
reasonable accuracy by taking into account 
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1. The level of Blood Pressure. 
2. The biological nature of hypertension based on target organ damage. 
3. The co-existence of other cardiovascular risk factors. (Jackson, et 
a11993) 
 
The goal of anti-hypertensive therapy should not only be 
reduction of blood pressure but also treating other risk factors. The major 
cardiovascular risk factors indicated in JNC-7 report are: 
• Hypertension 
• Cigarette smoking 
• Obesity 
• Physical inactivity 
• Dyslipidemia 
• Diabetes mellitus 
• Microalbuminuria or estimated GFR 60 < ml/min 
• Age (> 55 for men,>65 for women) 
• Family history of premature cardiovascular disease (<55 for men, 
<65 for women) 
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URIC ACID 
Purines arise from metabolism of dietary and endogenous 
nucleic acids, and are degraded ultimately to uric acid in man, through 
the action of the enzyme xanthine oxidase   Uric acid is a weak acid 
(pKa 5.8)  
Purines 
Nucleic acids (DNA, RNA) are made up of polynucleotide 
chain. These nucleotides are composed of purine or pyramidine bases. 
The various purine bases are: Adenine, Gaunine, Hypoxanthine and 
Xanthine. 
Synthesis of Purines 
Humans can synthesize purines from amphibolic intermediates. 
Purines are not dietarily essential. The purines are contributed by 3 
sources: 
• Denovo synthesis 
• Dietary nucleic acids 
• Cellular nucleic acid 
Denovo Purine Synthesis 
The atoms of purine ring are contributed by compounds 
including amino acids (aspartic acid, glycine and glutamine), CO2 and 
derivates of tetrahydrofolate. The purine ring is constructed by 11 step 
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process that results in, the formation of inosine mono phosphate (IMP). 
IMP can be converted to either adenosine monophosphate (AMP) or 
Guanine mono phosphate (GMP). The first step involves synthesis of 
phosphoribosyl pyrophosphate (PRPP). Next step involves synthesis of 
phosphoribosyl amine from PRPP and glutamine and is catalysed by 
the enzyme amido phosphoribosyl transferase. This is the rate limiting 
step in purine synthesis. 
Salvage Pathway for Purines 
All the purines are not degraded to uric acid. Purines that result 
from normal turnover of cellular nucleic acids can be reconverted to 
nucleotides and used by the body. Two enzymes Adenine 
phosphoribosyl transferase (APRT) and Hypoxanthine gaunine 
phosphoribosyl transferase (HGPRT) are involved. Deficiency of 
HGPRT causes Lesch-Nyhan syndrome 
Uric Acid Metabolism  
The total dynamic urate metabolic pool in the body is about 
1200 mg expressed as uric acid of which denovo synthesis contributes 
about 300-600 mg and dietary purines contributes about 600-700 mg. 
Each day about 2/3 of the uric acid are excreted in the urine and 1/3 is 
destroyed by bacterial uricolysis in the gut. 
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Degradation of Purines - Production of Uric Acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                       
 
 
.  
 
AMP 
Adenosine  
Pi 
Inosine  
Purine nucleoside 
Phospholysae  
Hypoxanthine  
Xanthine Oxidase 
uricacid
GMP 
Guanosine   
Gaunine  
Xanthine   
Pi 
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The total body urate pool 
 
 
 
 
 
 
 
 
Intestine 
 
 
 
Urate anion is freely filtered at the renal glomerular and kidney 
handles urate by following 
i. Glomurular filtration of 100% of the filtered load 
ii. Proximal tubular absorption - of 99% of filtered load. 
iii. Tubular secretion of about 50% of filtered load 
iv. Post secretary reabsorption of about 40% of filtered load. 
The net clearance of uric acid is around 10% of the filtered load 
and is in the range of 6 to 11 ml min/ 1.73 m2. 
Denovo synthesis  Nucleic acid   
Nucleotides 
Nucleosides 
Bases  
Urate  
Urine Intestine 
Salvage pathways  
Diet  
Tophi  
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Plasma Urate Levels: 
As mentioned urates, the ionized forms of uric acid predominate 
in plasma extra cellular fluid and synovial fluid with approximately 
98% existing as monosodium urate at PH 7.4.  
Normal serum uric acid level in males ranges from3.1to 7mg/dl 
and in females from 2.5 to 5.6mg/dl. 
          Plasma is saturated with monosodium urate at a concentration of 
415 micromol/L (6.8 mg/dl) at 37°C. At higher concentrations, plasma 
is therefore supersaturated, creating the potential for urate crystal 
precipitation. However, precipitation sometimes does not occur even at 
concentrations as high as 4800 µmol/L (80mg/dl), perhaps because of 
the presence of solubilizing substances in plasma. 
Plasma urate levels rises at puberty with female values being 
lower than in men until menopause after when it gradually rises to 
male value. It decreases during pregnancy. Hyperuricemia is a 
characteristic and often an early feature of pre-eclampsia. 
Extrinsic factors, particularly diet, plumbism, the prevalence of 
high ethanol intake in the community and diseases like malaria, 
thalassemia can affect plasma urate distribution in different 
populations. Epidemiological studies show significant variations in 
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plasma urate concentrations between different ethnic groups. For 
example, Polynesians have higher values than western Europeans and 
Americans. This illustrates the genetic, presumably, polygenic aspects 
in the control of serum uric acid. Other epidemiological studies 
emphasize the importance of environmental factors of purine, protein 
and alcohol intake. For example Gress and Zollner (1991) showed that 
the cumulated frequency of plasma urate rose from 6.2 mg/dL to about 
9.0 mg/dl between 1962-1971 in association with improved nutritional 
state of Bovarian population. 
The frequency distribution of plasma urate values based on 
asymptomatic population is only approximately gaussian, with an 
excess of higher values due to inclusion of some asymptomatic 
hyperuricaemic subjects. Ignoring the slight asymmetry of the 
frequency distribution and defining normality as the mean value + 2SD 
above the mean, normal upper limit of 7.0 mg/dL (420 f.1moVL) for 
men and 6.0 mg/dL (360 f.1moVL) for women is widely adopted. 
Hyperuricemia 
Hyperuricemia can result from increased production or 
decreased excretion of uric acid or from a combination of the two 
processes. When sustained hyperuricemia exists, plasma and extra 
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cellular fluids are super saturated with respect to urate and total body 
urate is increased.  
Physicochemically, hyperuricemia is the concentration of urate 
in the blood that exceeds the solutions limits of monosodium urate in 
plasma, 415 mol/l (6.8mg/dl). In epidemiological studies, 
hyperuricemia is defined as the mean plus 2 standard deviations of 
values determined from a randomly selected healthy population. 
Hyperuricemia is present between 2.0 and 13.2 % of ambulatory adults 
and some what more frequently in hospitalized individuals. 
CLASSIFICATION OF HYPERURICEMIA: 
Reduced renal excretion 
1. An inherited defect in renal handling of urate. 
2. Renal glomerular disease 
3. Renal tubular dysfunction  
• Tubulointerstitial nephritis 
• Competition for tubule excreting mechanism  
(Lactic acidosis and keto acidosis) 
• Drugs ( Diuretics, Pyrazinamide, Ethambutol etc.,) 
4. Other conditions in which renal tubular dysfunction has been 
proposed are 
• Hypertension 
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• Sickle cell anemia 
• Myxoedema 
• Lead nephropathy 
Increased-Uric acid production 
• Dietary sources 
• Hypoxanthine phosphoribosyl transferase deficiency 
• Increased phosphoribosyl pyrophosphate activity 
• Glycogen storage disorders 
• Hereditary fructose intolerance 
• Myeloproliferative diseases 
• Chronic hemolytic anaemias 
• Extensive psoriasis 
• Gauchers disease 
The following abnormalities are commonly associated with but 
not casually related to Hyperuricemia. 
• Obesity 
• Dyslipidemia (usually type 4 with increased VLDL and 
normal cholesterol) 
• Hypertension 
• Insulin resistance 
• Ischemic heart disease 
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URIC ACID AND CARDIOVASCULAR DISEASE 
        Over recent years there has been renewed debate about the nature 
of the association between raised serum uric acid concentration and 
cardiovascular disease. Several large studies have identified the value, 
in populations, of serum uric acid concentration in predicting the risk 
of cardiovascular events, such as myocardial infarction. This has 
directed research towards the potential mechanisms by which uric acid 
might have direct or indirect effects on the cardiovascular system. It 
has been difficult to identify the specific role of elevated serum uric 
acid because of its association with established cardiovascular risk 
factors such as hypertension, diabetes mellitus, hyperlipidaemia and 
obesity. 
            Indeed, it is not even clear at this stage whether uric acid has a 
damaging or protective effect in these circumstances. Increased 
understanding of the mechanisms underlying these associations may 
allow a clearer interpretation of the importance of elevated serum uric 
acid concentrations, and the potential value of specific urate-lowering 
treatment of cardiovascular disease.  
Nearly 120 years have elapsed since uric acid was first described 
as a potential factor in the development of cardiovascular disease 
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(Gerteler, et al 1951). Much but not all epidemiological research 
identifies hyperuricemia as an independent risk factor for the 
development of cardiovascular disease and renal disease, particularly 
in patients with hypertension or congestive heart failure and in women 
(Aldermen, 2002, Cohen, et al 1999, Freedman et al 1995). 
     Observational studies show that serum uric acid concentrations are 
higher in patients with established coronary heart disease compared 
with healthy controls. Elevated serum uric acid concentrations are also 
found in healthy offspring of parents with coronary artery disease, 
indicating a possible causal relationship.  
     However, hyperuricaemia is also associated with possible 
confounding factors including elevated serum triglyceride and 
cholesterol concentrations, blood glucose, fasting and post-
carbohydrate plasma insulin concentrations, waist-hip ratio and body 
mass index. About one quarter of hypertensive patients has co-existent 
hyperuricaemia and, interestingly, asymptomatic hyperuricaemia 
predicts future development of hypertension, irrespective of renal 
function. (Q J Med 2000; 93: 707-713) 
         There are certain clinical clustering groups with increased 
cardiovascular risk, which have associated Hyperuricemia. 
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They are (Hayden, et al 2004) 
• African American patient group 
• Patient groups with excessive alcohol 
• Hypertensive patient groups 
• Non diabetic patient groups with accelerated atherosclerosis 
• Congestive heart failure patient groups with ischemic 
cardiomyopathy. 
• Metabolic syndrome patient groups (with hyper insulinemia, 
impaired glucose tolerance, obesity, dyslipidemia, and 
hypertension). 
• Renal disease patient groups and  
• Patients groups taking diuretics. 
Each of these clustering groups has metabolic mechanisms that 
may help to explain which serum uric acid may be elevated. In addition 
to the recurring finding of an elevated tension of Oxidative - redox 
stress and reactive oxygen species in many of the groups is the 
importance of the metabolic syndrome and insulin resistance.  
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Uric Acid in Hypertension: 
Hypertension is strongly associated with hyperuricemia. Cannon 
et al (1966) reported that hyperuricemia was observed in 25% of 
untreated hypertensive subjects, 50% of those on treatment, and 75% to 
100% of those with malignant hypertension or renal dysfunction 
Potential mechanisms involved with the association of 
Hyperuricemia and hypertension include the following  
1. Decreased renal blood flow (decreased GFR) stimulating urate 
absorption (Mersserli, et al, 1980). 
2. Microvascular (capillary) disease resulting in local tissue ischemia 
(Puig, Ruilope, 1999) 
3. Ischemia with associated increased lactate production that blocks urate 
secretion in the proximal tubule and increased uric acid synthesis due 
to increased RNA – DNA breakdown and increased purine 
metabolism. 
4. Ischemia induces increased xanthine oxidase production. 
Other factors which may contribute are alcohol abuse (Ramsay, 
1979), lead intoxication, obesity and insulin resistance (Galvan et al, 
1995) and diuretic use. (Hypertension. 2005; 45:18.)  
            Most mammals have a low serum uric acid level because of the 
presence of uricase, a hepatic enzyme that degrades uric acid to 
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allantoin. However, in humans the uricase gene is mutated, resulting in 
uric acid levels that are both higher and less regulatable than in other 
mammals. Interestingly, when mild hyperuricemia was induced in rats 
by the administration of a uricase inhibitor, they became hypertensive. 
Further studies showed that the hypertension in this model was 
mediated by 2 mechanisms.  
              The first mechanism resulted from uric acid–induced renal 
vasoconstriction mediated by endothelial dysfunction with reduced NO 
levels and by activation of the renin-angiotensin system. This 
hypertension type is salt-resistant in that it occurs even in the presence 
of a low-salt diet, and it responds to lowering of uric acid.Later, 
however, the hyperuricemia causes progressive renal microvascular 
disease (a lesion resembling arteriolosclerosis), and once sufficient 
narrowing of the arteriolar lumen occurs, a component of the 
hypertension becomes salt-driven, renal-dependent, and independent of 
uric acid levels.  
               Finally, further studies demonstrated that this microvascular 
disease resulted from direct effects of uric acid, in that the urate was 
shown to enter into the vascular smooth muscle cell where it caused 
cell proliferation, activated the local renin-angiotensin system, and 
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stimulated the production of various inflammatory mediators including 
CRP and monocyte chemoattractant protein-1. 
            Mild hyperuricemia causes hypertension and renal injury in the 
rat via a crystal-independent mechanism, with stimulation of the renin-
angiotensin system and inhibition of neuronal NO synthase.( Marilda 
Mazzali et al ;Hypertension. 2001;38:1101.) 
It is also possible that metabolic perturbations like 
Hyperinsulinemia or sympathetic activity may produce alterations in 
renal sodium handling, leading to increased arterial pressure, decreased 
renal blood flow and decreased uric acid secretion. This in turn, 
increases purine oxidation, which results in increased reactive oxygen 
radicle, subsequent vascular injury and reduced nitric oxide. 
           
         Hyperuricemia and Renal Injury 
Renal injury occurs in Hyperuricemic rats, consisting of afferent 
arteriolopathy, mild tubulo interstitial fibrosis, glomerular hypertrophy 
and eventually, glomerulosclerosis and albuminuria. The renal changes 
are prevented if serum uric acid is maintained in the normal range with 
allopurinol. Increased serum uric acid has been found to predict the 
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development of renal insufficiency in individuals with normal function 
(Johnson, et al, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Adapted from ward, Lancer 1998) 
 
 
Sympathetic Outflow Hyperinsulinemia 
Altered renal 
Sodium handling 
↑ Arterial pressure  
↓ Renal blood flow 
↓ Uric acid excretion  
Serum Uric Acid  Early Hypertensive 
Neprosclerosis  
↑ Purine  Oxidation 
↑ Reactive oxygen 
spieces 
Hypertensive vascular injury  
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          Uric acid as a marker of insulin resistance 
      Insulin resistance syndromes result in attenuation of insulin-
mediated glucose utilization and confer a substantial increase in 
cardiovascular risk, through activation of several pathways including 
the sympathetic nervous system. Elevated serum uric acid is consistent 
feature of the insulin resistance syndromes, which are also 
characterized by elevated plasma insulin level (fasting and post-
carbohydrate), blood glucose concentration, and serum triglyceride 
concentration, and raised body mass index and waist-hip ratio.  
         Insulin has a physiological action on renal tubules, causing 
reduced sodium and uric acid clearance. Despite blunting of the action 
of insulin on glucose metabolism, sensitivity to the renal effects 
persists. Because plasma insulin concentration is characteristically 
elevated, hyperuricaemia may arise as a consequence of enhanced renal 
insulin activity. Elevated serum uric acid concentrations predict 
subsequent development of diabetes mellitus and hypertension, even in 
the presence of normal creatinine clearance and plasma glucose 
concentrations, and therefore may be a subtle, early marker of 
peripheral insulin resistance syndromes.  
37 
 
             Thus a link between elevated serum uric acid concentration and 
cardiovascular disease may arise through its non-causal relationship 
with insulin resistance syndromes, where cardiovascular risk is 
mediated by other factors.  
Hyperuricemia has been associated with increasing body mass 
index (BMI). Bedir A et aI, have recently described the role of leptin as 
possibly being a regulator of serum uric acid levels in humans.  
         Uric Acid as One of the Multiple Injurious Stimuli To The  
Endothelium of the Arterial Vessel Wall and Capillary: 
The upper 1/3 of the normal physiologic - homeostatic range (> 
4 mg /dl) and abnormal elevations (> 6.5 or 7 mg /dl in men and> 6.0 
mg/dl in women) in serum uric acid definitely should be considered as 
one of the multiple injurious stimuli to the arterial vessel wall and 
capillary, which may contribute to endothelial dysfunction and vessel 
wall remodeling through oxidative redox stress. (Hayden, 2002; Fang, 
Alderman 2000). 
Uric Acid as Antioxidant: 
An important observation was that uric acid may function as an 
ANTIOXIDANT, and possibly one of the most important antioxidants 
in plasma. Urate can scavenge superoxide, hydroxyl radical and singlet 
oxygen and can chelate transition metals. Peroxynitrite is a particularly 
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toxic product formed by the reaction of superoxide anion with nitric 
oxide that can injure cells by nitrosylating the tyrosine residues. Uric 
acid can block this. Recently Hink et al (Ulrich Hink et aI, 2002 ) 
reported that uric acid may also prevent the degradation of 
extracellular superoxide dismutase ( SOD3) an enzyme critical in 
maintaining endothelial function. SOD3 removes reactive oxygen 
spieces and thus helps in maintaining Nitric Oxide levels. Normally 
SOD3 is inactivated in the presence of H202 but uric acid blocks SOD 
inactivation and regenerates SOD3. 
The simple concept that elevated serum uric acid in patients with 
cardiovascular disease and hypertension may reflect a compensatory 
mechanism to counter oxidative stress in intriguing. However this does 
not explain why higher serum uric acid levels in patients are generally 
associated with worse outcomes (Johnson, ET al2003). 
An Antioxidant – Pro oxidant Urate Redox Shuttle: 
Antioxidants may become prooxidants in certain situations 
(Bagnati, et. a1.1999; Patternson et al 2003). Hayden et al proposes the 
existence of an antioxidant pro oxidant redox shuttle in the vascular 
milieu of atherosclerotic macrovessel intima.  
Serum Uric Acid in the early stages of the atherosclerosis 
process is known to act as an antioxidant (Nyyssonen, et al. 1997) 
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However, later in the atherosclerotic process when uric acid levels are 
known to be elevated (in the upper 1/3 of normal range more than 
4mg/dl and outside of the normal range > 6 mg /dl in females and 6.5 - 
7 mg/dl in males), this previously antioxidant paradoixcally becomes 
pro oxidant. This urate redox shuttle seems to rely on its surrounding 
environment - the accelerated atherosclerotic vulnerable plaque in the 
intima, which is acidic depleted of local antioxidants, with an increase 
in the oxidative stress, all those makes uric acid a pro oxidant. 
         Endothelial Dysfunction: 
The endothelium is an elegant symphony responsible for the 
synthetics and secretion of several biologically active molecules. It is 
responsive for the regulation of vascular tone, inflammation, lipid 
metabolism, vessel growth, endothelial matrix remodelling and 
modulation of coagulation and fibrinolysis. One particular enzyme 
system seems to act as the maestro: The endothelial nitric oxide 
systhase (e NOS) enzyme and its omnipotent product: Endothelial 
Nitric oxide (e NO). 
This endothelial nitric oxide synthase (e NOS) enzyme reaction 
is of utmost importance in maintaining endothelial function. When this 
enzyme system uncouples, the endothelium becomes a net producer of 
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superoxide and reactive oxygen spieces instead of net production of 
nitric oxide. 
The antioxidant pro oxidant urate redox is one of the causes of 
uncoupling of this enzyme system.  
 
Uric Acid, Vascular Smooth Muscle Proliferation and 
Inflammation:  
Uric acid stimulates rat smooth muscle cell proliferation in vitro. 
Uric acids enters smooth muscle cell by organs transporters. Inside the 
smooth muscle all it activates specific mitrogen activated protein 
kinases (Erk ½) with denovo induction of cyclo oxygenase - 2 (Cox - 
2), local thromboxane formation and with upregulation of platelet 
derived growth factor - A (PDGF-A) and C chain and PDGF alpha - 
receptor mRNA) 
Soluable uric acid is also pro inflammatory Uric acid stimulates 
synthesis of monocyte chomoattractant protein - 1 (MCP - 1) in rat 
vascular smooth muscle cell and by activating P 38 MAP Kinase and 
the nuclear transcription factors NF - KB. MCP-l is a chemokine that is 
important in vascular disease and atherosclerosis. Soluable uric acid 
also stimulates the production of interleukin -1 Beta, interleukin-6 and 
tumour factor (TNF). 
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         Elevations of uric acid> 4mg/dl should be considered a "red flag" 
in those patients at risk for cardiovascular diseases and should alert the 
clinician to strive to utilize a global risk reduction program to reduce 
the complications of the atherogenic process (Melvin R Hayden 2004). 
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AIMS AND OBJECTIVES 
 
1. To study the level of uric acid in patients with essential hypertension  
 
2. To identify whether any association exists between ages, sex, body 
mass index, smoking, diabetes and target organ damage and the 
presence of elevated serum uric acid.  
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MATERIALS AND METHODS  
 
Setting Government Rajaji Hospital and 
Madurai Medical College, 
Madurai. 
Collaborative 
Department  
Department of Biochemistry,  
Madurai Medical College, Madurai 
Study design  Cross sectional study 
Period of Study  March2009 to august2009 
Sample Size  225 cases 
Ethical committee 
approval  
The Present project was approved 
by the ethical committee 
Conflict of interest             
Financial Support             
 
NIL   
NIL   
 
Inclusion Criteria: 
• Patients with Essential hypertension  
• Patients whose ages were above 25 years were included  
• Both sexes were included.  
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          Exclusion Criteria: 
• Individuals below 25 years were excluded  
• Patients with renal failure  
• Pregnancy 
• Patients with secondary hypertension. 
• Patients who were on long-term diuretics. 
• Patients who were regular consumer of alcohol. 
• Patients who were on anti metabolite  and chemotherapy 
Controls 
Subject whose ages were above 25 years and had normal blood 
pressure and who met the above exclusion criterion.  
         Consent  
The study group thus identified by the above criteria (inclusion 
and exclusion criteria) was first instructed about the nature of the 
study. Willing participants were taken up after getting a written 
informed consent from them. 
Materials 
Thus a total of 150 cases that satisfied the inclusion and 
exclusion criteria above were taken up for subsequent study. 75 age 
and sex matched subjects were kept as control. 
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Limitations 
1. In this study, both newly detected as well as known cases of essential 
hypertension that were on treatment were included in the study.  
2. The study population included patients with essential hypertension 
both with and without target organ damage and other cardiovascular 
risk factors but without renal failure. 
3. Diagnosis of peripheral vascular disease was made on clinical 
examination only. Doppler study was not performed in every case due 
to technical limitation.  
4. Only serum uric acid levels were analyzed. Urinary urate excretion and 
urate clearance was not done. 
         Methods 
Selected Socio-demographic, clinical and laboratory data were 
elicited from the patients and controls and recorded in a proforma 
(enclosed in Annexure -Annexure-I)  
I. Socio-demographic data 
• Age 
• Sex 
II. Clinical data 
• Body mass index                           
• Systolic and diastolic blood pressure 
46 
 
• Cardiovascular risk factors 
• Clinical examination 
         III. Laboratory data 
• Blood Urea Estimation done manually by using Diacetyl 
monoxime (DAM) technique. 
• Serum creatinine  Estimation was done using COBAS auto 
analyzer  
• Serum uric acid  Enzymatic method (semi auto analyzer) 
Principle: 
Uric acid is converted by uricase to allantoin and hydrogen 
peroxide in the presence of peroxidase (POD) oxidises the chromogen 
to a red coloured compound which is read at 500 mm. 
 
Uric acid + 2H2O + O2 Uricase  Allantoin + CO2 + H202 
 2H202 + 4 Aminoantipyrine + DHBS POD Red quinolone + 
H2O+ HCI (DHBS - 3, 5 - Dichloro - 2 - Hydroxy benzene sulphonic 
acid). 
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DEFINITIONS USED IN THE PRESENT STUDY 
 
1) Essential Hypertension 
According to the JNC- VII report, Hypertension is defined as 
systolic blood pressure of 140mm Hg and above and or diastolic blood 
pressure of 90 and above. In newly detected cases it was the mean of 3 
relaxed, seated right arm readings. The diagnosis that the hypertension 
is essential and not secondary was made on the over all clinical 
impression only. Laboratory investigations to rule out secondary 
causes were not done in each case.  
2) Hyperuricemia  
Hyperuricemia is defined as serum uric acid levels> 7mg/dl in 
males and >6mg/dl in females.  
3) Over weight / Obesity. 
• Over weight - Body mass index of ≥ 23 
• Obesity - Body mass index> 25 ( York et al ) 
4) Diabetes Mellitus 
• Already a known case of diabetes mellitus on treatment 
• Fasting plasma glucose ≥126mg/dl  
• Two hour plasma glucose  ≥ 200mg/dl 
• Symptoms of diabetes plus random blood glucose  ≥ 200mg/dl 
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5) Left ventricular hypertrophy 
Based on electrocardiographic findings satisfying either 
Sokolon-Lyon criteria or Cornell voltye criteria (Sokolan, Lyon, 1949) 
(Casale, et al, 1987) 
 
6) Hypertensive retinopathy 
Based on Keith-Wagner-Barker grading  
Grade I- attenuation of arteries. 
Grade II-arterio-venous nipping. 
Grade III-with hemorrhage and exudates. 
Grade IV-with papiledema. 
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RESULTS 
 
        This study group included total number of 225 subjects. Among 
these 225 subjects, 150 were cases (hypertensives) and 75 were 
controls (normotensives).  
ANALYSIS OF CASES AND CONTROLS WITH RESPECT 
OF TO THE AGE 
Table 1 Distribution of age among cases and controls              
                               
 
 
 
 
         
       The age of the subjects in this study group ranged from 26 to 79 
years. The mean and standard deviation of age for cases and controls were 
54.57 ±12.438 and 52.13 ±9.82 respectively. 
       There was no significant (p value = 0.128) difference in the age 
composition of those with and without hypertension in this study. Hence 
elevated serum uric acid among cases and controls was independent of 
age.   
 
 GROUP           NO.
           AGE T  TEST 
     P 
VALUE MEAN  S.D 
CASES 150 54.57 12.438       
0.128 
CONTROLS 75 52.13 9.820 
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    SEX DISTRIBUTION IN THE STUDY POPULATION   
 
      Table 2 Distribution of study population in relation to gender 
   
 
    SEX 
                 CASES                CONTROLS 
        NO PERCENTAGE            
NO. 
PERCENTAGE
MALE 110 73.3 49 65.3 
FEMALE 40 26.7 26 34.7 
TOTAL 150 100 75 100 
 
        
        Among the 150 cases studied, there were 110 males and 40 females.        
Among the 75 controls, there were 49 males and 26 females. In the study 
population, 69.2% of males were hypertensives, while in females 60.6% 
were hypertensives. 
    There was no significant (P-value= 0.139) difference in the sex   
distribution among cases and controls. 
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ANALYSIS OF CASES AND CONTROLS WITH RESPECT TO 
BODY MASS INDEX (BMI) 
 
Table 3 BMI Distributions In The Study Population  
 
  
                 
BMI  
CASES CONTROLS T TEST  
(P VALUE ) 
NO % NO % 
< 23 74         49.3 44 58.7  
 
     0.063 
≥23 
TOTAL 
76 
150 
        50.7 
       100 
31 
75 
41.3 
100 
MEAN 
   S.D. 
23.404 
3.9589 
22.416 
1.9555 
 
 
 
           The mean and standard deviation of BMI for cases and controls 
were 23.4±3.96 and 22.42±1.96 respectively. 30% of cases were obese 
while in the control group it was 12%. 
        The difference in Body Mass Index between cases and controls were 
statistically not significant (p-0.063). 
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                   SYSTOLIC BP IN RELATION TO SERUM URIC ACID IN STUDY GROUP 
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BLOOD PRESSURE DISTRIBUTION AMONG CASES AND 
CONTROLS 
 
Table 4 Distribution of systolic and diastolic BP among study group 
   
Blood 
Pressure 
Group     No    Mean    S.D 
SYSTOLIC BP 
  
CASES 150 163.87 16.916 
10.819 CONTROLS 75 116.72 
DIASTOLIC BP 
  
CASES 150 101.68        8.954 
7.656 CONTROLS 75 75.36 
PULSE  
PRESSURE 
  
CASES 150 62.1867 13.69534 
CONTROLS 75 41.3600 10.43466 
 
       The mean and standard deviation of systolic and diastolic BP in 
cases were 163.87±16.92 and 101.68±8.95 respectively. 
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DISTRIBUTION OF CASES AND CONTROLS IN RELATION TO 
CARDIOVASCULAR RISK FACTORS 
 
           In this study population family history of cardiovascular disease, 
smoking and diabetes mellitus were equally prevalent in both cases and 
controls. 
Table 5 Distribution of study population in relation to cardiovascular 
risk factors.  
 
                CASES         CONTROLS P VALUE
COUNTS      % COUNTS       % 
FAMILY 
H/O 
YES 
NO 
     22 
   128 
   14.7 
   85.3 
    18 
    57 
    24 
    76 
  0.184 
 
SMOKING 
H/O 
YES 
NO 
     52 
    98 
   34.7 
   65.3 
    33 
    42 
    44 
    56 
0.173 
DIABETIC 
H/O 
YES 
NO 
   28 
  122 
   18.7 
   81.3 
    12 
    63 
    16 
    84 
0.622 
 
           
              
           There was no statistical significance between cases and controls in 
relation to family history of cardiovascular disease, smoking and diabetes. 
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Distribution of cases and controls in relation to blood 
sugar,urea and serum Creatinine. 
 
 Table 6 Distribution of study population in relation to blood parameters 
        NO.  MEAN           SD       P 
BL.SUGAR 
 
CASES 150 105.25 37.920  
0.374 CONTROLS 75 101.15 17.620
BL.UREA 
 
CASES 150 29.04 5.601  
 
0.201 CONTROLS 75 28.11 4.072
SR.CREAT 
 
CASES 150 0.947 0.2113  
 
0.370 CONTROLS 75 0.923 0.1538
 
 
        There was no statistical significance in distribution of cases and controls 
in relation to Blood sugar, urea and serum creatinine. 
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ANALYSIS OF CASES IN RELATION TO TARGET ORGAN 
DAMAGE (TOD) 
      The details of prevalence of target organ damage (TOD) - Left ventricular 
hypertrophy (LVH), Coronary artery disease (CAD), Congestive cardiac 
failure (CCF), Cerebrovascular accident/Transient ischemic attack 
(CVA/TIA), Peripheral arterial disease (PAD) and Hypertensive retinopathy. 
        Table 7 Distribution of cases in relation to TOD  
         TOD            Cases 
     No.  Percentage
 LVH        Present 22 14.7 
Absent 128 85.3 
 
CAD 
Present 53 35.3 
Absent 97 64.7 
 
CCF 
Present 22 14.7 
Absent 128 85.3 
 
CVA/TIA 
Present 24 16 
Absent 126 84 
 
PAD 
Present 4 2.7 
Absent 146 97.3 
 
Retinopathy 
NIL 87 58 
Grade I 37 24.7 
Grade II 24 16 
Grade III 2 1.3 
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               Among 150 cases, LVH was present in 22 cases, CAD was present 
in 53 cases, CCF was present in 22 cases, CVA/TIA was present in 24 cases, 
PAD was present in 4 cases and Hypertensive Retinopathy was present in 
63cases. 
 
 
Table 8 Distribution of serum uric acid among study population 
 
 Group      No.     Mean    SD P-value  
SR.URIC 
ACID 
  
CASES      150 5.185 1.3104                      
0.0001 
 
CONTROLS 
     75 3.853 0.7006 
 
              Serum uric acid in cases varied from 3.1mg% to 9mg% and in the 
control from 2.8mg% to 5.9mg%. The mean and standard deviation of serum 
uric acid among cases were 5.185±1.31 while in control it was 3.853±0.7 
respectively. This table clearly shows that the serum uric acid level was 
significantly influenced by systemic hypertension. 
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                           SERUM URIC ACID IN RELATION TO SYSTOLIC BP IN STUDY GROUP 
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                 SERUM URIC ACID IN RELATION TO DIASTIOLIC BP IN STUDY GROUP 
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DISTRIBUTION OF CASES AND CONTROLS IN RELATION TO 
HYPERURICEMIA 
Table 9 Comparisons of mean uric acid levels among  the cases and  
controls 
 
URICEMIC  
 STATUS 
  N MEAN 
STD. 
DEVIATION P VALUE 
NORMAL 
  
CASES 129 4.790 0.8982 
0.0001 
CONTROLS 75 3.853 0.7006 
HYPER 
URICEMIA 
  
CASES 21 7.611 0.6654 
 
- 
CONTROLS 
0(A)      -                  - 
(A) - T CANNOT BE COMPUTED BECAUSE AT LEAST ONE OF THE GROUPS IS EMPTY. 
       
           Hyperuricemia is defined as serum uric acid levels >7mg/dl in males 
and >6mg/dl in female. 21 cases had hyperuricemia while none of the 
controls had hyperuricemia. Mean and SD of hyperuricemia in cases 
7.6±0.67. Hyperuricemia was present in 14%of hypertensives. 
    This table clearly shows hyperuricemia was statistically significant in 
hypertensives when compared to normotensives. 
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SEX DISTRIBUTION OF SERUM URIC ACID IN STUDY 
POPULATION 
Table 10 Comparision Of Uric Acid Levels Amongs the Study Groups 
 
GROUP SEX N 
SR URIC ACID 
P VALUE MEAN SD 
CASES FEMALES 40 5.047 1.2643
0.438 
  MALES 110 5.236 1.3289
CONTROLS FEMALES 26 3.700 0.5741
0.169 
  MALES 49 3.935 0.7521
 
      The mean serum uric acid level in hypertensive males and females were 
5.24±1.33 and 5.05±1.26 respectively. 
      Even though the mean serum uric acid level was higher in hypertensive 
males when compared to hypertensive females it was not statistically 
significant. 
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                  SERUM URIC ACID IN RELATION TO BMI  IN STUDY GROUP 
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SERUM URIC ACID IN RELATION TO BODY MASS INDEX 
      In the study population, BMI <23 was seen in 74 cases among 118 
subjects, and the mean serum uric acid level was 5.16±1.4. BMI ≥23 was 
seen in 76 cases among 107 subjects and and the mean serum uric acid level 
was 5.2±1.18.  
 
 Table No-11: Relationship Between BMI and Uric Acid Level in cases 
and controls 
  
 Study 
group 
Serum uric 
acid 
 Cases Serum uric 
acid 
 
BMI No. Mean S.D PVALUE No. Mean S.D pVALUE 
<23 118 4.73 1.37  
0.917 
74 5.18 1.4  
0.925 ≥23 107 4.75 1.24 76 5.2 1.18 
 
 
      This table shows Body Mass Index was not significantly influencing the 
serum uric acid. 
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Table 12 Serum uric acid Levels in relation to smokers in  
study population  
 H/o Smoking 
Absent Present 
Serum Uric  
Acid 
 
Normal  Count  124 79 
Percentage  88.6 92.9 
Hyperuricemia Count  16 6 
Percentage  11.4 7.1 
Chi Square test : p= 0.108 
 Serum uric acid   
H/o smoking  No. Mean S.D. pValue  
YES  85 4.77 1.27 0.873 
NO 140 4.73 1.33 
 
 
          This table showed smoking did not influence serum uric acid level 
significantly. 
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 Hyperuricemia was present in 7.1% of smokers in study population. 
The mean serum uric acid level of smokers in study population was 4.77 ±1.3 
when compared to non smoker 4.73±1.33. 
 
Table 13 Serum uric acid levels in Diabetes Mellitus among  
study population  
 H/o Smoking 
Absent Present 
Serum Uric  
Acid 
 
Normal  Count  169 34 
Percentage  91.4 85 
Hyperuricemia Count  16 6 
Percentage  8.6 15 
 
Chi Square test : p=0.288 
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Table 14 Serum uric acid levels in Diabetes Mellitus among  
study population  
 Serum uric acid  
H/o smoking No. Mean S.D. pValue  
YES 40 4.85 1.35 0.573 
NO 185 4.72 1.3 
 
 Hyperuricemia was present in 15% of Diabetics in study population. 
The mean serum uric acid level of Diabetics in study population was 
4.85±1.3. 
 
 This table showed Diabetes did not influence serum uric acid level 
significantly.  
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Serum uric acid level in relation to Target Organ Damage (TOD) 
The mean values and standard deviation of target organ damage which was 
present in cases were shown in table below.  
 
Table 15 Serum uric acid level in relation to target organ damage.  
TOD No. Mean S.D. P-value 
LVH 
YES 22 5.29 1.34 
0.635 
NO 128 5.14 1.29 
CAD 
YES 53 5.56 0.02 
0.01 
NO 97 4.98 0.01 
CCF 
YES 22 5.85 1.57 
0.0965 
NO 128 5.18 1.22 
CVA/TIA 
YES 24 4.73 1.13 
0.064 
NO 126 5.27 1.33 
Retinopathy 
YES 63 4.97 1.13 
0.075 
NO 87 4.56 1.28 
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Coronary arterial disease was seen in 53 hypertensive individuals. The 
mean serum uric acid level in cases with CAD was 5.56±0.02 while it was 
4.98±0.01 among the cases without CAD. There was significant difference 
noticed among the cases with and without CAD (P-value 0.01). 
 
 There was no significant difference noticed among the cases with and 
without other target organ damages like LVH, CCF, CVA, and 
RETINOPATHY. 
 
 Peripheral arterial disease was seen in 4 hypertensive individuals only. 
The mean serum uric acid level in cases with PAD was 7.26±0.6 while it was 
5.23±1.29 among the cases without PAD.  
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Serum uric acid level in hypertensive subjects with and without Target 
Organ Damage (TOD). 
 
Table 16 Serum uric acid level in cases with/without TOD 
TOD No Mean S.D P-value 
Present  112 5.21 1.41 
0.701 
Absent  38 5.114 0.93 
 
 The mean serum uric acid level in hypertensive subjects with and 
without TOD was 5.21±1.4 and 5.114±0.93 respectively. The serum uric acid 
level in cases with and without target organ damage was not statistically 
significant (P-value 0.701) 
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Discussion  
 Hypertension is the most common form of cardiovascular disease 
which is present in nearly 25% of adults and the prevalence increases with 
age. Hypertension is strongly associated with hyperuricemia (Hayden, 2004). 
Cannon et al (1966) reported that hyperuricemia was observed in 25% of 
untreated hypertension or renal dysfunction.  
 In the study the relation between serum uric acid level and 
hypertension was analyzed. Previous strong epidemiological data had linked 
serum uric acid level and hypertension (Cannon et al 1966, Kinsley et al, 
1961, Klein et al, 1973) and experimental animal data suggested 
hyperuricemia causes hypertension (Mazzali et al 2001, Sanchezs et al 2002, 
Watanable, 2002).  
 Among the 150 cases of hypertension, hyperuricemia was seen in 21 
cases, which is account for 14% of cases. Cannon et al 1966 showed a 
prevalence of hyperuricemia in 25% of untreated hypertensive cases. But in 
our study many of the cases were on treatment which might have affected the 
results.  
 The experimental studies further showed that hyperuricemia caused 
preglomerular vascular disease via BP independent pathway (Mazzali et al 
2001) and once vascular disease was established, the hypertension was driven 
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by kidney and lowering uric acid level was no longer protective (Watanable, 
2002) 
 The observation from the Framingham study revealed that the 
correlation of uric acid level with blood pressure was attenuated in the study 
population as they aged is consistent with these data. (Source : Feig and 
Johnson 2003). 
 Various studies have linked the development of hypertension with 
hyperuricemia. The Olivetti heart study (Joss et al, 1994) has shown an 
independent positive association between serum uric acid and development of 
hypertension. Selby, et al, (1990) have concluded in their study that both 
forced vital capacity and serum uric acid were closely linked to the 
development of hypertension.  
 Feig and Johnson et al (2003) found that serum uric acid was elevated 
in 89% of children with essential hypertension. He concluded that serum uric 
acid level directly correlated with blood pressure in untreated children and 
that a serum uric acid level of >5.5mg% in an adolescent being evaluated for 
hypertension strongly suggests essential hypertension. 
The mean age for cases in this study is 54.57 years. This might 
explain the lower prevalence of hyperuricemia when compared with Feig 
and Johnson et al study (2003).  
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The mean serum uric acid level in male is 5.24±1.33 while in female 
it is 5.05±1.26 and the difference is not statistically significant. This is in 
contrast with the study done by Ketker et al (1979) in which they have 
shown that the serum uric acid level was more in males when compared to 
females. 
In this study serum uric acid do not correlate with Body Mass Index. 
The mean serum uric acid level in hypertensive with BMI<23 and BMI≥23 
are 5.175mg/dl and 5.195mg/dl and the difference is not statistically 
significant. Shobha Kelker et al and Healey have shown in their study that 
there was no significant correlation between serum uric acid level and 
obesity. 
The serum uric acid level is significantly higher in hypertensives 
when compared to normotensive subjects. The mean serum uric acid level in 
cases is 5.185mg/dl while in the control it is 3.85mg/dl. This is consistent 
with other studies, which has shown serum uric acid is elevated in 
hypertension. 
In a review article by Hayden et al (2004) it was noted that 
elevation of serum uric acid level >4mg/dl should be considered as a red 
flag in those cases with risk for cardiovascular disease. In this study 82%of 
hypertensive has serum uric acid level >4mg/dl, while in controls 36% of 
subjects have serum uric acid level >4mg/dl. In these subjects the clinician 
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should strive to utilize global risk reduction programme to reduce the 
complications of atherogenic process. The details in relation to this study are 
shown in the table given below. 
 
Table 17 Distribution cases and controls in relation to high risk serum 
uric acid: 
Serum uric
acid 
Cases Controls P-value 
 
0.0001 
No. % No. % 
≤4mg/dl 27 18 48 64 
>4mg/dl 123 82 27 36 
 
       The association of serum uric acid with cardiovascular disease has been 
appreciated for nearly half a century (Gertler et al, 1951). However, its role as 
a cardiovascular risk factor remains controversial. The Framingham heart 
study concluded that uric acid does not have a causal role in the development 
on coronary heart disease and death from other cardiovascular disease. In an 
epidemiologic follow up study an association between serum uric acid and 
cardiovascular disease was shown (Fredman et al). The recent PIUMA study 
also concluded that raised serum uric acid is a powerful risk factor for 
subsequent cardiovascular disease and all cause mortality 
(PaolaVerdecchia,et al,2000). 
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       A large body of evidence links uric acid with the metabolic syndrome of 
insulin resistance, obesity, hypertension and dyslipidemia.Cappuccio et al 
reported an association of hyperuricemia with increased renal tubular sodium 
reabsorption, thus providing a link with hyperuricemia, hypertension and 
hyperinsulinemia. However there is no significant association between serum 
uric acid level and diabetic in this study. Smoking which is also a 
cardiovascular risk factor does not significantly influence serum uric acid 
level in the present study. (Hypertension. 2005; 45:991-996) 
             Overall, patients with target organ damage had significantly higher 
levels of serum uric acid as compared with those without it. But in our study, 
the serum uric acid level in cases with and without target organ damage is not 
statistically significant (P-value0.701). 
      Hyperuricemia is more pronounced in hypertensives complicated by PAD 
and is associated with worse functional status of the peripheral circulation 
(Atherosclerosis.2003 may; 168(1):163-8) 
      In our study, peripheral arterial disease is seen in 4 hypertensive 
individuals only. The mean serum uric acid level in cases with PAD is 
7.26±0.6 while it is 5.23±1.29 among the cases without PAD. 
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     Adenosine synthesis and release are up regulated in response to hypoxia 
and tissue ischemia. The adenosine is rapidly degraded by endothelium to 
uric acid. Therefore hyperuricemia is considered as a marker of underlying 
tissue ischemia (Waring et al2000).    
      The Subjects with altered Coronary Flow Rate (CFR) had significantly 
higher SUA levels compared with those with normal CFR These results 
support a role for SUA level as an independent marker of target organ 
damage in hypertension (Mustafa Caliskan, Dogan Erdogan et al). 
   Serum uric acid levels are independently and significantly associated with 
risk of cardiovascular mortality (JAMA. 2000; 283:2404-2410). 
  In our study, coronary arterial disease is seen in 53 hypertensive individuals. 
The mean serum uric acid level in cases with CAD is 5.56±0.02 while it is 
4.98±0.01 among the cases without CAD. There is significant difference 
noticed among the cases with and without CAD (Pvalue- 0.01). 
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        Hyperuricemia, a known correlate of oxidative stress, is a marker for 
adverse prognosis among individuals with heart failure. Hyperuricemia is a 
novel, independent risk factor for heart failure in a group of young general 
community dwellers. This has implications for development of preventive 
strategies for heart failure (Circulation: Heart Failure. 2009; 2:556-562) 
         As there are controversies with reference to elevated uric acid as an 
independent risk factor for cardiovascular disease, it is suggested to carry out 
similar prospective studies among newly detected hypertensive population 
and follow them to ascertain truth. 
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CONCLUSION 
1. Hyperuricemia (>7mg/dl in males and >6mg/dl in females) is found in 
14% of hypertensives while none of the normotensives had hyperuricemia.   
2. Serum uric acid level is significantly elevated in Essential hypertension. 
3. There is no correlation between serum uric acid with age, gender, body 
mass index, smoking, and Diabetes. 
4. Serum uric acid level is significantly elevated in cases with coronary artery 
disease /peripheral arterial disease as compared to those with other target 
organ damage. 
5. In this study, 82% of hypertensive population having Serum uric acid level 
>4mg/dl which is now considered as a red flag in those with risk factor for 
cardiovascular disease.  
 
 
 
 
 
 
83 
 
 
BIBLIOGRAPHY 
 
1. Agamah ES, Srinivasan SR, Webber LS, Berenson GS. Serum uric 
acid and its relation to cardiovascular disease risk factors in children 
and young adults from a biracial community: the Bogalusa Heart 
Study. J Lab Clin Med1991; 118:241–9. 4. Emmerson BT. The 
management of gout. N Engl J Med1996; 334:445–515. Steele TH. 
Hyperuricemic nephropathies. Nephron1999; 81 (Suppl. 1):45–9. 
2. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid 
and cardiovascular events in successfully treated hypertensive patients. 
Hypertension1999; 34:144–50 
3. Alper AB, Chen W, Yau L, Srinivasan S, Hamm LL, Berenson G. 
Childhood uric acid predicts adult blood pressure: The Bogalusa Heart 
Study. Hypertension. 2005; 45: 34–38. 
4. Anker SD, Leyva F, Poole-Wilson PA, Kox WJ, Stevenson JC, Coats 
AJ. Relation between serum uric acid and lower limb blood flow in 
patients with chronic heart failure. Heart1997; 78:39–43. 
5. Beard JT. Serum uric acid and coronary heart disease. Am Heart 
J1983; 106:397–400. 
84 
 
6. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia 
and risk of cardiovascular disease and overall death. A 12-year follow-
up of participants in the population study of women in Gothenburg, 
Sweden. Acta Med Scand1988; 224:549–55. 
7. Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, Tosi F, 
Travia D, Zenti MG, Branzi P, Santi L, Muggeo M. Relationship of 
uric acid concentration to cardiovascular risk factors in young men. 
Role of obesity and central fat distribution. The Verona Young Men 
Atherosclerosis Risk Factors Study. Int J Obes Relat Metab 
Disord1996; 20:975–80. 
8. Boogaerts MA, Hammerschmidt DE, Roelant C, Verwilghen RL, 
Jacob HS. Mechanisms of vascular damage in gout and oxalosis: 
crystal induced, granulocyte mediated, endothelial injury. Thromb 
Haemost1983; 50:576–80. 
9. Bulpitt CJ. Serum uric acid in hypertensive subjects. Brit Heart J. 
1975; 37: 1210–1215. 
10. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. 
Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966; 
275: 457–464. 
85 
 
11. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and 
risk for cardiovascular disease and death: the Framingham Heart 
Study. Ann Intern Med1999; 131:7–13. 
12. Dobson A. Is raised serum uric acid a cause of cardiovascular disease 
or death? Lancet1999; 354:1578. 
13. Duff GW, Atkins E, Malawista SE. The fever of gout: urate crystals 
activate endogenous pyrogen production from human and rabbit 
mononuclear phagocytes. Trans Assoc Am Physicians1983; 96:234–
45. 
14. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship 
between resistance to insulin-mediated glucose uptake, urinary uric 
acid clearance, and plasma uric acid concentration. JAMA. 1991; 266: 
3008–3011 
15. Feig DI, Johnson RJ. Hyperuricemia in childhood essential 
hypertension. Hypertension. 2003; 42: 247–252. 
16. Ferro CJ, Webb DJ. Endothelial dysfunction and hypertension. 
Drugs1997, 53(Suppl. 1): 30–41. 
17. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Metabolic precursors 
of hypertension. The San Antonio Heart Study. Arch Intern Med. 1996; 
156: 1994–2001 
86 
 
18. Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an 
increased risk of future hypertension in Utah. A screening analysis. 
Hypertension. 1991; 17: 969–976 
19. Hutton CW, Collins AJ, Chambers RE, Whicher J, Dieppe PA. 
Systemic response to local urate crystal induced inflammation in man: 
a possible model to study the acute phase response. Ann Rheum 
Dis1985; 44:533–6. 
20. Iribarren C, Folsom AR, Eckfeldt JH, McGovern PG, Nieto FJ. 
Correlates of uric acid and its association with asymptomatic carotid 
atherosclerosis: the ARIC Study. Atherosclerosis Risk in Communities. 
Ann Epidemiol1996; 6:331–40. 
21. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, 
Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there 
a pathogenetic role for uric acid in hypertension and cardiovascular 
and renal disease. Hypertension. 2003; 41: 1183–1190. 
22. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, 
Mancini M, Trevisan M. Serum uric acid and hypertension: the Olivetti 
heart study. J Hum Hypertens. 1994; 8: 677–681. 
23. Kahn HA, Medalie JH, Neufeld HN, Riss E, Goldbourt U. The 
incidence of hypertension and associated factors: the Israel ischemic 
heart disease study. Am Heart J. 1972; 84: 171–182 
87 
 
24. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley 
A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid 
stimulates monocyte chemoattractant protein-1 production in vascular 
smooth muscle cells via mitogen-activated protein kinase and 
cyclooxygenase-2. Hypertension. 2003; 41: 1287–1293 
25. Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tryoler HA. 
Serum uric acid. Its relationship to coronary heart disease risk factors 
and cardiovascular disease, Evans County, Georgia. Arch Intern Med. 
1973; 132: 401–410. 
26. Kohn PM, Prozan GB. Hyperuricemia: relationship to 
hypercholesterolemia and acute myocardial infarction. JAMA1959; 
170:1909–15. 
27. Kroll K, Bukowski TR, Schwartz LM, Knoepfler D, Bassingthwaighte 
JB. Capillary endothelial transport of uric acid in guinea pig heart. Am 
J Physiol1992, 262:H420-H431. 
28. Lee J, Sparrow D, Vokonas PS, Landsberg L, Weiss ST. Uric acid and 
coronary heart disease risk: evidence for a role of uric acid in the 
obesity-insulin resistance syndrome. The Normative Aging Study. Am 
J Epidemiol. 1995; 142: 288–294 
88 
 
29. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a 
strong predictor of stroke in patients with non-insulin-dependent 
diabetes mellitus. Stroke1998; 29:635–9. 
30. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, 
Poole-Wilson PA, Coats AJ. Uric acid in chronic heart failure: a 
marker of chronic inflammation. Eur Heart J1998; 19:1814–22. 
31. Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U. 
Association of serum uric acid with all-cause and cardiovascular 
disease mortality and incident myocardial infarction in the MONICA 
Augsburg cohort. World Health Organization Monitoring Trends and 
Determinants in Cardiovascular Diseases. Epidemiology1999; 10:391–
7. 
32. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric 
acid and plasma norepinephrine concentrations predict subsequent 
weight gain and blood pressure elevation. Hypertension. 2003; 42: 
474–480 
33. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, 
Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood 
pressure in the rat by a novel crystal-independent mechanism. 
Hypertension. 2001; 38: 1101–1106. 38. Mazzali M, Kanellis J, Han L, 
Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, 
89 
 
Nakagawa T, Lan HY, Johnson RJ. Hyperuricemia induces a primary 
renal arteriolopathy in rats by a blood pressure-independent 
mechanism. Am J Physiol Renal Physiol. 2002; 282: F991–F997. 
34. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, 
Rosano GM. Effect of hyperuricemia upon endothelial function in 
patients at increased cardiovascular risk. Am J Cardiol. 2004; 94: 932–
935 
35. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. 
Serum uric acid in essential hypertension: an indicator of renal 
vascular involvement. Ann Intern Med. 1980; 93: 817–821. 
36. Muscelli E, Natali A, Bianchi S, Bigazzi R, Galvan AQ, Sironi AM, 
Frascerra S, Ciociaro D, Ferrannini E. Effect of insulin on renal 
sodium and uric acid handling in essential hypertension. Am J 
Hypertens1996; 9:746. 
37. Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, Ohya Y, Takishita 
S. Hyperuricemia as a predictor of hypertension in a screened cohort in 
Okinawa, Japan. Hypertens Res. 2004; 27: 835–841. 
38. Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-
Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ. 
Hyperuricemia causes glomerular hypertrophy in the rat. Am J 
Nephrol. 2003; 23: 2–7. 
90 
 
39. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. 
Serum uric acid and risk for development of hypertension and impaired 
fasting glucose or Type II diabetes in Japanese male office workers. 
Eur J Epidemiol. 2003; 18: 523–530. 
40. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, 
Williams GH, Hollenberg NK, Fisher ND. Uric acid and the state of 
the intrarenal renin-angiotensin system in humans. Kidney Int. 2004; 
66: 1465–1470. 
41. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro 
D, Ferrannini E. Effect of insulin on uric acid excretion in humans. Am 
J Physiol. 1995; 268: E1–E5 
42. Raatikainen MJ, Peuhkurinen KJ, Hassinen IE. Contribution of 
endothelium and cardiomyocytes to hypoxia-induced adenosine 
release. J Mol Cell Cardiol1994; 26:1069–80. 
43. Reunanen A, Takkunen H, Knekt P, Aromaa A. Hyperuricemia as a 
risk factor for cardiovascular mortality. Acta Med Scand Suppl1982; 
668:49–59. 
44. Sánchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, 
Nepomuceno T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J. 
Mild hyperuricemia induces vasoconstriction and maintains glomerular 
hypertension in normal and remnant kidney rats. Kidney Int. 2004. 
91 
 
45. Selby JV, Friedman GD, Quesenberry CPJ. Precursors of essential 
hypertension: pulmonary function, heart rate, uric acid, serum 
cholesterol, and other serum chemistries. Am J Epidemiol1990; 
131:1017–27 
46. Short RA, Tuttle KR. Clinical evidence for the influence of uric acid 
on hypertension, cardiovascular disease, and kidney disease: a 
statistical modeling perspective. Semin Nephrol. 2005; 25: 25–31 
47. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in 
slowing the progression of renal disease through its ability to lower 
serum uric acid level. Am J Kidney Dis. 2006; 47: 51–59. 
48. Skinner KA, White CR, Patel R, Tan S, Barnes S, Kirk M, Darley-
Usmar V, Parks DA. Nitrosation of uric acid by peroxynitrite. 
Formation of a vasoactive nitric oxide donor. J Biol Chem1998; 
273:24491–7. 
49. Sundström J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan 
RS. Relations of serum uric aid to longitudinal blood pressure tracking 
and hypertension incidence in the Framingham Heart Study. 
Hypertension. 2005; 45: 28–33. 
50. Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. 
Serum uric acid and the risk for hypertension and type 2 diabetes in 
92 
 
Japanese men: The Osaka Health Survey. J Hypertens. 2001; 19: 
1209–1215. 
51. The Coronary Drug Project Research Group. Serum uric acid: its 
association with other risk factors and with mortality in coronary heart 
disease. J Chron Dis1976; 29:557–69. 
52. Torun M, Yardim S, Simsek B, Burgaz S. Serum uric acid levels in 
cardiovascular diseases. J Clin Pharm Ther1998; 23:25–9. 
53. Tykarski A. Evaluation of renal handling of uric acid in essential 
hypertension: hyperuricemia related to decreased urate secretion. 
Nephron1991; 59:364–8. 
54. Vaccarino V, Krunholz HM. Risk factors for cardiovascular disease: 
one down, many more to evaluate. Ann Int Med. 1999; 131: 62–63. 
55. Vallance P. Nitric oxide in the human cardiovascular system- SKB 
lecture 1997. Br J Clin Pharmacol1998; 45:433–9. 
56. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk 
of major coronary heart disease events. Heart1997; 78:147–53. 
57. Ward H. Uric acid as an independent risk factor in the treatment of 
hypertension. Lancet1998, 352:670–1. 
 
 
93 
 
                                                   PROFORMA 
 
         NAME:                          AGE:              SEX:                  IP/OP No:                    
         BMI:                
         COMPLAINTS:     
         PAST HISTORY: 
                     DIABETES MELLITUS:                                                               
                     CAD: 
                     CVA/TIA: 
           
         HISTORY OF SMOKING: 
 
         FAMILY HISTORY:  
 
         EXAMINATION:           
                    BLOOD PRESSURE:                 ALL PERIPHERAL  PULSES: 
                    CCF: 
                    CVA/TIA:                                                FUNDUS: 
               
         INVESTIGATIONS: 
                    ECG: 
                    BL.SUGAR:                BL.UREA:                 SR.CREATININE: 
                    SR.URIC ACID:                                              
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ABBREVIATIONS 
 
BMI:Body Mass Index. 
S.B.P:Systolic blood pressure. 
D.B.P:Diastolic blood pressure. 
FAMILY.H: Family history. 
DM:Diabetes mellitus. 
LVH:Left ventricular hypertrophy. 
CAD:Coronary artery disease. 
CCF:Congestive cardiac failure. 
CVA:Cerbrovascular accident. 
TIA:Transient ischemic attack. 
PAD:Peripheral arterial disease. 
RETINO:Retinopathy. 
RBS:Random blood sugar. 
BL.UREA:Blood urea. 
S.CREAT:Serum creatinine. 
SUA:Serum uric acid. 
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1 61 F 31.7 160 100 NO NO NO NO YES NO NO NO II 71 40 0.7 4.2 
2 52 F 21.1 150 90 NO NO NO NO NO NO NO NO NIL 89 30 0.9 4 
3 55 M 17.4 160 100 NO YES NO NO NO NO YES NO II 96 30 1.4 5.5 
4 46 F 27.6 150 100 NO NO NO NO YES NO NO NO NIL 108 20 0.8 4.5 
5 41 M 16.6 160 110 NO YES NO NO NO NO YES NO I 90 23 1.1 5.2 
6 44 M 22.7 160 110 YES YES NO NO NO YES NO NO NIL 95 26 0.9 4.7 
7 47 M 16.8 210 110 NO YES NO NO YES NO NO NO III 120 40 1.4 6.2 
8 59 M 25.3 170 84 YES NO NO NO YES NO NO NO NIL 118 36 1.1 3.5
9 63 M 26.5 150 90 NO YES NO NO YES NO NO NO NIL 88 30 1.1 4.8 
10 55 M 23.6 170 100 NO NO YES NO YES YES NO YES II 170 40 0.8 7.42 
11 51 M 20.5 170 110 NO YES NO NO NO NO YES NO NIL 77 28 1 5.2 
12 59 M 24.1 190 120 NO NO NO NO NO NO NO NO I 89 32 1.1 5.5 
13 48 M 19.9 160 100 YES NO NO NO NO NO YES NO NIL 110 22 0.7 5.3 
14 30 M 21.8 170 100 NO YES NO NO NO NO NO NO I 112 24 0.9 4.7 
15 40 M 22.4 160 120 NO NO NO NO NO NO YES NO NIL 98 18 0.9 3.6 
16 62 M 25.2 150 100 NO YES NO NO NO NO NO NO NIL 105 30 1 4.8 
17 59 M 24.8 160 100 NO YES YES NO NO YES NO NO I 162 26 1.1 4.6 
18 60 M 23.6 160 100 NO NO YES NO NO NO NO NO NIL 180 30 0.8 4.4 
19 48 M 22.1 164 100 YES YES NO NO YES NO NO NO NIL 77 24 0.9 6.5 
20 33 M 21.9 146 90 NO YES NO NO NO YES NO NO I 125 40 1 4.5 
21 74 M 27.5 160 100 NO NO NO NO NO NO NO NO I 74 20 0.9 7.7 
22 55 M 32.8 170 110 NO YES YES YES YES NO NO NO NIL 203 30 0.8 6.4 
23 70 M 23.3 150 100 NO NO NO YES YES NO NO NO II 68 19 0.7 4.1 
24 54 M 24 160 100 YES YES YES YES NO NO NO NO I 179 30 0.7 4.6 
25 26 M 27.4 150 100 NO NO NO NO NO NO NO NO NIL 90 26 0.8 5.8 
26 64 M 22.5 186 106 NO NO NO NO NO NO YES NO NIL 115 26 0.9 3.7 
27 55 M 27.7 190 120 NO NO NO YES NO NO NO NO II 104 40 1 6.2 
28 65 F 16.4 166 110 NO NO NO NO NO NO NO NO I 79 24 0.8 6.8 
29 40 F 24.3 164 96 NO NO NO NO NO NO NO NO NIL 92 30 0.9 5.7 
30 42 F 20.7 150 100 NO NO NO NO NO NO NO NO NIL 78 24 0.8 5.5 
31 50 F 19.4 180 100 NO NO NO NO NO NO YES NO NIL 87 22 0.7 4.3 
32 26 M 24.8 156 90 NO NO NO NO NO NO NO NO NIL 70 30 1 5.9 
33 30 M 22.5 148 100 NO NO NO NO NO NO NO NO NIL 74 24 0.9 6 
34 62 M 25.2 150 90 NO NO NO NO NO NO NO NO NIL 88 24 0.8 5.8 
35 63 M 31.1 150 100 NO YES NO NO NO NO NO NO NIL 106 28 1 6.2 
36 55 M 21.5 140 100 NO NO NO NO YES NO NO NO NIL 96 30 0.8 6.4 
37 63 M 25 180 100 YES NO NO NO YES NO NO NO I 114 24 1 5.5 
38 74 M 22.8 150 92 NO NO NO NO YES NO NO NO NIL 109 26 0.7 3.9 
39 60 M 27.2 170 110 NO YES NO NO YES NO NO NO I 83 32 0.8 5.2 
40 70 M 32.8 150 100 NO NO NO NO NO NO NO NO NIL 117 28 0.7 4.1 
41 67 M 24.6 160 100 NO YES NO NO NO NO NO NO NIL 73 28 1 3.9
42 55 M 23.4 170 80 NO NO NO NO NO NO NO NO NIL 99 30 1.1 5.1 
43 51 F 27.3 170 90 NO NO NO NO NO NO NO NO II 101 29 0.9 4.9 
44 40 F 22.4 160 100 NO NO NO NO NO NO NO NO NIL 65 24 0.9 7 
45 63 F 26.7 150 90 NO NO NO NO NO NO NO NO NIL 82 30 1.1 5.5 
46 48 M 22 170 100 NO YES NO NO YES YES NO NO NIL 110 28 1 8.8 
47 45 F 24.9 166 96 NO NO YES NO NO NO NO NO I 167 30 0.9 6.5 
48 30 M 22.4 160 100 YES NO NO NO YES NO NO NO NIL 94 26 0.7 8.4 
49 47 M 21.6 156 96 NO NO NO NO NO NO NO NO NIL 101 20 0.8 4.5 
50 28 F 27.1 140 100 NO NO YES NO YES NO NO NO NIL 217 32 0.7 7.35 
51 56 M 15.8 180 100 NO YES NO YES NO NO NO NO II 66 40 1.5 4.9 
52 63 M 22.7 180 100 YES NO NO NO YES NO YES NO I 74 34 1.3 4.8 
53 60 F 16.9 170 80 NO NO NO NO YES YES YES NO I 67 28 0.7 4.5 
54 48 M 20.4 170 120 NO YES NO NO YES YES NO NO II 73 30 0.7 7.5
55 39 M 25.3 146 90 YES NO YES NO YES NO NO NO II 69 29 1.2 5.3 
56 66 M 22.2 140 100 NO YES NO YES YES YES NO NO I 83 32 1.4 5.5 
57 48 M 20.8 150 110 NO NO YES NO NO NO NO NO NIL 134 24 0.8 3.9 
58 65 M 23.5 230 130 NO YES NO YES NO NO YES NO II 72 26 0.8 7.62 
59 79 M 19.8 210 120 NO NO NO YES NO YES NO YES NIL 70 38 1.5 7.4 
60 49 M 21.9 140 100 NO YES NO NO YES NO NO NO NIL 69 30 1.3 4.6 
61 60 M 22.8 150 100 NO YES YES NO YES YES NO NO NIL 220 26 1 4.1 
62 60 F 27.2 210 120 YES NO NO YES NO NO YES NO I 145 40 1.3 4.3 
63 45 F 33.8 150 100 NO NO YES NO YES YES NO NO NIL 180 34 1 5.6 
64 62 F 23.2 144 100 NO NO YES NO NO NO NO NO NIL 185 32 0.8 4.4 
65 38 M 23.4 160 90 NO YES YES NO YES NO NO NO NIL 112 26 0.9 4.8 
66 54 F 27.3 170 110 NO NO YES YES NO NO NO NO NIL 172 24 0.8 3.1 
67 61 M 22 160 100 NO YES NO NO NO NO YES NO I 96 25 0.9 3.3 
68 65 M 28.4 170 100 NO NO NO NO NO NO NO NO NIL 79 40 1 4.95 
69 70 M 16.1 170 100 NO NO NO NO YES NO NO NO NIL 83 35 1.1 3.24 
70 49 F 24.3 160 100 NO NO NO NO NO NO NO NO I 69 19 0.6 4.1 
71 65 M 18.6 170 100 NO YES NO NO NO NO NO NO II 95 24 0.9 3.66 
72 67 M 16.9 180 100 YES NO NO YES NO NO NO NO NIL 87 21 1 4.15
73 56 F 23.8 150 100 NO NO NO NO NO NO NO NO I 72 20 0.8 3.44 
74 53 M 20.8 170 100 NO NO NO NO NO NO NO NO II 83 39 1.3 3.77 
75 45 F 25.1 150 100 NO NO NO NO YES NO NO NO I 78 29 0.8 3.44 
76 64 F 31.7 150 100 NO NO NO NO YES NO NO NO II 66 40 0.7 5.46 
77 48 F 22.5 160 110 NO NO NO NO NO NO NO NO NIL 104 26 0.8 4.25 
78 50 F 20 160 110 NO NO NO NO NO NO NO NO NIL 80 30 0.9 4.14 
79 65 M 16 160 100 NO YES NO NO NO NO YES NO II 94 33 1.3 4.15 
80 43 F 27.6 150 100 NO NO NO NO YES NO NO NO NIL 104 19 0.9 4.5 
81 40 M 15.6 160 110 NO YES NO NO NO NO YES NO I 88 23 1.1 5.3 
82 42 M 22.7 160 110 YES YES NO NO NO YES NO NO NIL 93 26 1 4.49 
83 45 M 16.9 210 110 NO YES NO NO YES NO NO NO III 118 40 1.2 6.3 
84 64 M 25.2 170 90 YES NO NO NO YES NO NO NO NIL 119 36 1.4 3.6 
85 60 M 26.3 150 90 NO YES NO NO YES NO NO NO NIL 86 30 1.1 4.3
86 56 M 22.6 190 110 NO NO YES NO YES YES NO YES II 170 40 0.6 7.8 
87 52 M 20.9 170 90 NO YES NO NO NO NO YES NO NIL 76 28 0.9 5.3 
88 60 M 24.1 160 100 NO NO NO NO NO NO NO NO I 88 32 1.2 5.6 
89 46 M 19.9 150 100 YES NO NO NO NO NO YES NO NIL 108 22 0.7 5.2 
90 30 M 21.8 170 100 NO YES NO NO NO NO NO NO I 112 24 1.1 4.9 
91 40 M 22.4 140 110 NO NO NO NO NO NO YES NO NIL 96 18 0.9 3.8 
92 65 M 27.2 150 100 NO YES NO NO NO NO NO NO NIL 82 30 1 4.9 
93 58 M 24 160 100 NO YES YES NO NO YES NO NO I 162 26 1.1 4.6 
94 60 M 23.6 160 100 NO NO YES NO NO NO NO NO NIL 180 30 0.8 4.51 
95 48 M 21.9 170 100 YES YES NO NO YES NO NO NO NIL 72 24 0.9 6.6 
96 39 M 22.3 144 96 NO YES NO NO NO YES NO NO I 126 37 1 4.2 
97 73 M 27.3 160 100 NO NO NO NO NO NO NO NO I 72 22 0.9 7.45 
98 55 M 32.8 150 100 NO YES YES YES YES NO NO NO NIL 208 30 0.8 6.6 
99 70 M 23.3 146 100 NO NO NO YES YES NO NO NO II 60 25 0.7 4.5 
100 54 M 23.4 150 100 YES YES YES YES NO NO NO NO I 180 35 0.7 4.4 
101 28 M 27.4 150 100 NO NO NO NO NO NO NO NO NIL 80 20 0.8 5.2 
102 64 M 22.5 186 106 NO NO NO NO NO NO YES NO NIL 113 26 0.9 3.5 
103 55 M 27.7 160 100 NO NO NO YES NO NO NO NO II 100 39 1 6.3
104 65 F 16.1 166 110 NO NO NO NO NO NO NO NO I 81 25 0.8 7.2 
105 41 F 24.3 164 96 NO NO NO NO NO NO NO NO NIL 72 29 0.9 5.6 
106 45 F 20.2 140 100 NO NO NO NO NO NO NO NO NIL 70 24 0.8 5.2 
107 50 F 19 180 120 NO NO NO NO NO NO YES NO NIL 87 22 0.7 4.2 
108 27 M 24.8 156 100 NO NO NO NO NO NO NO NO NIL 65 31 1 6.5 
109 30 M 21.5 160 96 NO NO NO NO NO NO NO NO NIL 74 29 0.9 6.3 
110 62 M 25.2 166 100 NO NO NO NO NO NO NO NO NIL 88 23 0.8 6.2 
111 63 M 32.1 170 110 NO YES NO NO NO NO NO NO NIL 106 27 1 6.5 
112 55 M 21.5 160 100 NO NO NO NO YES NO NO NO NIL 96 30 0.8 6
113 63 M 25 180 100 YES NO NO NO YES NO NO NO I 112 25 1 6.3 
114 74 M 22.8 150 92 NO NO NO NO YES NO NO NO NIL 108 27 0.7 4.2 
115 60 M 27.2 170 110 NO YES NO NO YES NO NO NO I 80 35 0.8 5.1 
116 42 M 32.8 150 100 NO NO NO NO NO NO NO NO NIL 116 30 0.7 3.7 
117 61 M 24.6 146 100 NO YES NO NO NO NO NO NO NIL 72 27 1 3.9 
118 55 M 23.4 150 80 NO NO NO NO NO NO NO NO NIL 92 36 1.1 4.2 
119 51 F 27.3 150 90 NO NO NO NO NO NO NO NO II 108 29 0.9 4.9 
120 40 F 22.4 170 100 NO NO NO NO NO NO NO NO NIL 66 24 0.9 7.4 
121 63 F 27.7 170 100 NO NO NO NO NO NO NO NO NIL 75 33 1.1 5.2 
122 48 M 22 180 110 NO YES NO NO YES YES NO NO NIL 117 28 1 8.5 
123 45 F 24.9 140 100 NO NO YES NO NO NO NO NO I 166 32 0.9 5.3 
124 30 M 22.4 160 110 YES NO NO NO YES NO NO NO NIL 76 29 1 9 
125 56 M 20.6 156 96 NO NO NO NO NO NO NO NO NIL 118 28 0.8 4.6 
126 29 F 27 190 120 NO NO YES NO YES NO NO NO NIL 220 25 0.7 8.2 
127 57 M 15.6 150 90 NO YES NO YES NO NO NO NO II 69 40 1.5 4.9 
128 63 M 22.7 180 100 YES NO NO NO YES NO YES NO I 75 34 1.3 4.9 
129 60 F 16.9 170 90 NO NO NO NO YES YES YES NO I 88 30 0.7 4.5 
130 47 M 20.4 170 120 NO YES NO NO YES YES NO NO II 78 26 0.9 7.5 
131 53 M 26.3 180 110 YES NO YES NO YES NO NO NO II 80 31 1.2 5.2 
132 66 M 22 170 110 NO YES NO YES YES YES NO NO I 78 34 1.4 5.3 
133 48 M 20.8 160 100 NO NO YES NO NO NO NO NO NIL 125 27 0.5 3.8 
134 65 M 23.5 230 130 NO YES NO YES NO NO YES NO II 83 29 0.8 7.7 
135 72 M 19.8 210 120 NO NO NO YES NO YES NO YES NIL 90 37 1.5 6.4
136 49 M 21.9 150 100 NO YES NO NO YES NO NO NO NIL 80 30 1.4 4.5 
137 60 M 22.3 150 100 NO YES YES NO YES YES NO NO NIL 205 30 1 4.2 
138 59 F 27.2 210 120 YES NO NO YES NO NO YES NO I 144 36 1.3 4.3 
139 47 F 32.8 174 110 NO NO YES NO YES YES NO NO NIL 179 28 1 6.6 
140 62 F 23.2 154 90 NO NO YES NO NO NO NO NO NIL 190 34 0.6 5.1 
141 39 M 23.4 160 90 NO YES YES NO YES NO NO NO NIL 115 28 1.1 5 
142 55 F 27.3 170 110 NO NO YES YES NO NO NO NO NIL 175 32 0.8 3.7 
143 61 F 22 160 100 NO YES NO NO NO NO YES NO I 116 27 0.9 3.4 
144 62 M 27.7 170 100 NO NO NO NO NO NO NO NO NIL 96 35 1 5.5 
145 70 M 16.1 170 110 NO NO NO NO YES NO NO NO NIL 81 34 0.9 3.3 
146 49 F 24.3 160 100 NO NO NO NO NO NO NO NO I 112 29 1 3.5 
147 65 M 18.6 170 100 NO YES NO NO NO NO NO NO II 96 25 0.8 3.9 
148 68 M 16.9 160 100 YES NO NO YES NO NO NO NO NIL 85 26 1.1 4
149 57 F 23.8 160 100 NO NO NO NO NO NO NO NO I 88 25 0.7 3.5 
150 52 M 20.8 150 90 NO NO NO NO NO NO NO NO II 110 42 1.2 3.8 
 
